Friday 6 November 2026 Export COSM’s income statement to Excel — free account

Cosmos Health Inc.

COSM Healthcare Medical Distribution

Cosmos Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.3 million, up 19.9% from fiscal 2024.

Revenue: +28.8%
EPS: 0.00%
Free cash flow: +9.39%
Total debt: +15.3%

Quarter to June 2026, against a year earlier

0.29 0.04 −12.12%

Follow COSM

Alert me

Market cap: $29.2M
P/E: 0.0×
Fwd P/E: −2.1×
Dividend yield: —
F-score: 5/9
Altman Z: −2.50
Beneish M: −3.25
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 1.55

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	2	7	2	—	—	—	3	2	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Size

Market Cap 29.18

Revenue ttm 73.73

Net income ttm (24.39)

Free cash flow ttm (12.45)

Net debt Q 9.30

Valuation

P/E 0.00

Forward P/E (2.05)

Price / sales 0.24

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.84

Financial health

Current ratio Q 1.05

Debt / equity Q 0.57

Interest coverage Q (2.91)

Growth

Revenue growth Q +28.76%

Operating income growth Q −10.60%

EPS, this year +76.19%

EPS, next year A +146.67%

Revenue, next year A +30.85%

EPS, past 5 yrs —

EPS, next 5 yrs A +62.88%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 33.74%

10-year low 10-year high

P/B against its own 10 years 60.27%

10-year low 10-year high

EV/Sales against its own 10 years 28.84%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	0	4	2
Receivables	21	15	22	21
Inventory	5	4	6	5
Other	—	—	—	—
	37	25	38	37

	2023	2024	2025	Q'26
Payables	12	12	17	14
ST’ Debt	7	7	9	9
Other	3	3	7	7
	24	26	38	35

Compound Annual Growth %

	10y	5y	3y
Sales	—	3.33%	9.04%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(22.31%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.01 Actual −0.03

−0.52 −0.37 −0.22 −0.07 0.08

Q2 FY24 Beat +0.05

Q3 FY24 Miss −0.34

Q1 FY26 Miss −0.01

Q2 FY26 Miss −0.04

Q3 FY26 — Nov 13

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q2 FY24	−0.14	−0.09	Beat by 0.05
Q3 FY24	−0.11	−0.45	Miss by 0.34
Q1 FY26	−0.01	−0.02	Miss by 0.01
Q2 FY26	0.01	−0.03	Miss by 0.04
Q3 FY26	−0.04	—	Reports 13 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.06)	(0.10)	—	—	—
’25	(0.03)	(0.10)	(0.17)	(0.31)	(0.63)
’24	(0.11)	(0.15)	(0.45)	(0.45)	(1.17)
’23	(0.04)	(0.09)	(0.27)	(1.73)	(2.15)
’22	(7.75)	(23.25)	(2.00)	(3.96)	(33.16)
’21	(3.61)	(3.69)	(2.83)	(1.99)	(23.74)
’20	(0.91)	2.60	1.43	(1.57)	1.54

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	18	19	—	—	—
’25	14	15	17	20	65
’24	15	13	12	14	54
’23	12	12	13	16	53
’22	13	13	12	12	50
’21	12	15	14	16	56
’20	12	13	14	16	55

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(2)	—	—	—
’25	0	(1)	(2)	(5)	(8)
’24	(3)	(1)	1	(4)	(8)
’23	(6)	(6)	(5)	1	(16)
’22	(2)	(1)	(2)	(10)	(15)
’21	(1)	(2)	(3)	(2)	(7)
’20	(1)	(5)	(4)	(1)	(12)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(1)	—	—	—
’25	0	(1)	(3)	(6)	(11)
’24	(3)	(1)	1	(5)	(9)
’23	(6)	(9)	(7)	(3)	(25)
’22	(2)	(1)	(2)	(10)	(15)
’21	(1)	(2)	(4)	(2)	(8)
’20	(1)	(5)	(4)	(1)	(12)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	7	30	37	40	55	56	50	53	54	65	74		+28.7%	85	130	161	+35.1%
	Gross margin, %	8.90	6.52	6.50	9.23	14.55	14.81	11.83	8.15	7.92	12.10	10.27		+3.2 pt	Powerpack Cosmos Health Inc.’s next three years, line by line Analysts expect revenue to grow 35.1% a year to 2028 — faster than the 28.7% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(1)	(6)	(9)	(3)	1	(8)	(13)	(19)	(16)	(19)	(24)		+46.9%
	EBT margin, %	(8.88)	(20.68)	(24.39)	(7.85)	2.16	(13.95)	(25.93)	(34.74)	(29.73)	(29.33)	(33.08)		(20.5) pt
	Net income	(1)	(6)	(9)	(3)	1	(8)	(14)	(19)	(16)	(19)	(24)		+46.9%
Per share, $
Per share, $	Revenue	13.44	58.71	69.67	74.73	104.38	85.61	26.11	4.46	2.84	2.16	1.23		(18.4%)
	Earnings	(1.20)	(12.15)	(17.02)	(6.21)	1.55	(23.74)	(33.16)	(2.15)	(1.17)	(0.63)	(0.64)		(6.9%)
	Cash flow	(4.23)	(17.14)	(2.92)	(9.02)	(21.67)	(10.80)	(7.71)	(1.31)	(0.40)	(0.28)	(0.16)		(26.1%)
	Capex	(0.03)	(0.11)	(0.95)	(1.27)	(0.22)	(1.36)	(0.19)	(0.77)	(0.07)	(0.07)	(0.04)		+12.1%
	Free cash flow	(4.26)	(17.24)	(3.87)	(10.29)	(21.89)	(12.16)	(7.90)	(2.07)	(0.47)	(0.35)	(0.21)		(24.2%)
	Book value	(3.49)	(5.92)	(6.23)	(12.17)	(7.84)	6.67	20.37	3.01	1.28	0.61	0.35		n/m
	Shares, m	1	1	1	1	1	1	2	12	19	30	42		+57.7%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	3.30	0.00	0.00	0.00	0.00	0.00	0.00		0.3
	P/S	0.61	4.60	1.44	0.74	0.05	0.98	0.21	0.31	0.24	0.23	0.24		0.9
	P/B	0.00	0.00	0.00	0.00	0.00	12.64	0.27	0.45	0.52	0.82	0.84		1.5
	EV/Sales	0.53	4.57	1.47	0.87	0.38	1.36	0.00	0.42	0.39	0.41	0.36		1.0
	EV/FCF	(1.67)	(15.57)	(26.47)	(6.29)	(1.81)	(9.96)	(0.01)	(0.90)	(2.34)	(2.52)	(2.14)		(6.8)
Cash, $m
Cash, $m	Operating cash flow	(2)	(9)	(2)	(5)	(12)	(7)	(15)	(16)	(8)	(8)	(10)		+16.6%
	Capex	0	0	(1)	(1)	0	(1)	0	(9)	(1)	(2)	(3)		+76.7%
	Free cash flow	(2)	(9)	(2)	(5)	(12)	(8)	(15)	(25)	(9)	(11)	(12)		+19.5%
Balance, $m
Balance, $m	Working capital	(2)	(4)	(4)	(7)	6	10	35	12	0	0	2		n/m
	Net debt	(1)	(1)	1	5	18	21	(11)	6	8	12	9		n/m
	Shareholders’ equity	(2)	(3)	(3)	(6)	(4)	4	39	36	25	18	21		n/m
Returns, %
Returns, %	ROA	(8.71)	(90.03)	(57.77)	(14.80)	2.42	(33.44)	(108.87)	(38.47)	(37.20)	(31.96)	(39.56)		(23.2) pt
	ROIC	0.00	0.00	0.00	0.00	11.94	(11.11)	(16.26)	(32.58)	(29.66)	(34.86)	(38.23)		(34.9) pt
	ROE	25.14	259.79	285.59	67.48	(15.46)	(14,274.32)	(292.90)	(68.46)	(73.88)	(89.13)	(104.00)		(114.3) pt
People
People	Employees	—	1	1	68	85	95	102	123	149	163	—		+89.0%
	Revenue/emp, $m	0.00	30.01	37.08	0.58	0.65	0.59	0.49	0.43	0.37	0.40	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 25 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HSIC Henry Schein, Inc.	$9.4B	22.8×	21.3×	+3.95% (above 0%: growing)	+34.81% (above 0%: growing)	−7.09% (below 0%: shrinking)	31.84%	5.56%	Compare
AHG Akso Health Group Sponsored ADR	$1.1B	— (loss-making)	— (loss-making)	+263.89% (above 0%: growing)	n/m	−12,975.04% (below 0%: shrinking)	0.00%	0.00%	Compare
FOCL FocalTherics	$159.3M	— (loss-making)	— (loss-making)	+38.85% (above 0%: growing)	n/m	+21.49% (above 0%: growing)	55.59%	(60.83%)	Compare
COSM Cosmos Health Inc.	$29.2M	— (loss-making)	— (loss-making)	+28.76% (above 0%: growing)	n/m	+9.39% (above 0%: growing)	7.96%	(15.41%)
ACH Accendra Health, Inc.	$23.0M	— (loss-making)	— (loss-making)	−10.07% (below 0%: shrinking)	n/m	−1,624.82% (below 0%: shrinking)	42.95%	(5.73%)	Compare
YI 111, Inc. Sponsored ADR	$15.5M	— (loss-making)	— (loss-making)	−29.61% (below 0%: shrinking)	n/m	−185.70% (below 0%: shrinking)	5.33%	(0.85%)	Compare
MEDS DataMeds AI, Inc	$5.5M	— (loss-making)	—	−77.15% (below 0%: shrinking)	n/m	−41.85% (below 0%: shrinking)	10.24%	(412.67%)	Compare
HKPD Cellyan Biotechnology Co., Ltd	$3.4M	—	—	—	—	−90.45% (below 0%: shrinking)	—	—	Compare
SNYRQ Synergy CHC Corp.	$1.3M	— (loss-making)	1.6×	−32.77% (below 0%: shrinking)	n/m	−148.51% (below 0%: shrinking)	72.29%	(10.32%)	Compare
Median of peers	$19.2M	—	—	−10.07%	—	−119.48%	31.84%	(5.73%)

All 12 Medical Distribution stocks →

Pay and ownership Proxy statement filed 2 June 2026

Ownership

Directors and executive officers, together 26.15%

Grigorios Siokas 21.88%

Andreas Bovopoulos 6.91%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Cosmos Health Inc. (COSM) Latest News

5 Nov

Impact 3 · 8:00 AM · ACCESS Newswire

Cosmos Health's CosmoFarm Begins Commissioning New Automated Order-Processing and Vehicle-Loading Infrastructure, Advancing Capacity That Could Support Over $120 Million in Annual Revenue

4 Nov

Impact 3 · 9:27 AM · ACCESS Newswire

Cosmos Health's Amazon UK Business Surpasses $2 Million in TTM Sales, Up 90%, with a 23% Net Profit Margin; Expects Sales to Grow Approximately 72% to $3.9 Million Over the Next Twelve Months

29 Oct

Impact 4 · 9:23 AM · ACCESS Newswire

Cosmos Health's U.S. Active Subscriptions Surpass 12,000, Up 92% in Two Weeks

28 Oct

Impact 4 · 9:20 AM · ACCESS Newswire

Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target

22 Oct

Impact 4 · 3:55 PM · ACCESS Newswire

Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway

20 Oct

Impact 4 · 12:15 PM · ACCESS Newswire

Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion

19 Oct

Impact 4 · 9:30 AM · ACCESS Newswire

Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days

14 Oct

Impact 4 · 9:30 AM · ACCESS Newswire

Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription

Impact 4 · 8:28 AM · Zacks Small Cap Research

COSM US Growth Impresses

13 Oct

Impact 4 · 9:30 AM · ACCESS Newswire

Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days

7 Oct

Impact 4 · 9:30 AM · ACCESS Newswire

Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million

Impact 4 · 9:14 AM · Zacks Small Cap Research

COSM Continues to Surge Revenue Growth

1 Oct

Impact 4 · 3:58 PM · ACCESS Newswire

Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion

29 Sep

Impact 4 · 1:03 PM · Zacks Small Cap Research

COSM Continues to Grow Business

Impact 4 · 9:30 AM · ACCESS Newswire

Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue

28 Sep

Impact 4 · 8:00 AM · ACCESS Newswire

Cosmos Health's Contract Manufacturing Division Surpasses $20 Million in Implied Revenue and $18 Million in Implied Gross Profit Across Its Record 32.7 Million-Unit Production Pipeline

15 Sep

Impact 4 · 10:30 AM

Cosmos Health Adds 5.2 Million Units in New Five-Year Agreements with Target Pharma; Orderbook Surges Past 32.7 Million Units, Up 31% Since June

14 Sep

Impact 4 · 3:59 PM

Cosmos Health Moves to Tokenize CCX0722 Intellectual Property in Innovative Non-Dilutive Structure, Eyes $562 Billion Weight-Management Market

11 Sep

Impact 4 · 11:10 AM

Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units

10 Sep

Impact 4 · 8:11 AM

COSM Again Expands its Market and Accelerates its Growth

9 Sep

Impact 4 · 9:30 AM

Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market

28 Aug

Impact 3 · 9:30 AM

Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions

24 Aug

Impact 4 · 3:40 PM

Cosmos Health Projects Over $6M in Annual Revenue and $4.3M in Gross Profit from Oliv18™ Across the U.S. Cardiovascular Health and Antioxidant Categories

20 Aug

Impact 4 · 9:30 AM

Cosmos Health Enters Saudi Arabia Through Exclusive Distribution Agreement With Innova Healthcare; Secures Initial Purchase Order of 126,000 Sky Premium Life Units, With More Than 5 Million Units Expected Over Initial 5-Year Term

19 Aug

Impact 4 · 9:00 AM

Cosmos Health Reports Q2 2026 Results: Record Q2 and H1 Revenue of $19.0M and $36.9M, Up 29% and 30%; Q2 Adjusted Gross Profit Up 58%; Total Liabilities Reduced 13%; Stockholders' Equity Up 12%; $5M Share Repurchase Program Underway

Impact 4 · 7:44 AM

COSM Produces Stellar Quarter

27 Jul

Impact 4 · 1:05 PM

Cosmos Health Advances Its Technology-Driven Transformation with an AI-Enabled Subscription Platform Across B2C and B2B Channels

24 Jul

Impact 3 · 7:06 AM

COSM Marking Huge Growth and Buying Back Shares

20 Jul

Impact 4 · 3:46 PM

Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units

15 Jul

Impact 3 · 2:15 PM

Cosmos Health Share Buyback Surpasses 4.5 Million Shares; Continues Open Market Repurchases

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Cosmos Health Inc. vs peers in Medical Distribution (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 2 June 2026

Ownership

Cosmos Health Inc. (COSM) Latest News

5 Nov

4 Nov

29 Oct

28 Oct

22 Oct

20 Oct

19 Oct

14 Oct

13 Oct

7 Oct

1 Oct

29 Sep

28 Sep

15 Sep

14 Sep

11 Sep

10 Sep

9 Sep

28 Aug

24 Aug

20 Aug

19 Aug

27 Jul

24 Jul

20 Jul

15 Jul

Stockrow Weekly